AUTHOR=Duron Emmanuelle , Vidal Jean-Sébastien , Grousselle Dominique , Gabelle Audrey , Lehmann Sylvain , Pasquier Florence , Bombois Stéphanie , Buée Luc , Allinquant Bernadette , Schraen-Maschke Susanna , Baret Christiane , Rigaud Anne-Sophie , Hanon Olivier , Epelbaum Jacques 

TITLE=Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ1–42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment

JOURNAL=Frontiers in Aging Neuroscience

VOLUME=10

YEAR=2018

URL=https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2018.00297

DOI=10.3389/fnagi.2018.00297

ISSN=1663-4365

ABSTRACT=<p>A combination of low cerebrospinal fluid (CSF) Amyloid β<sub>1–42</sub> (Aβ<sub>1–42</sub>) and high Total-Tau (T-Tau) and Phosphorylated-Tau (P-Tau) occurs at a prodromal stage of Alzheimer’s disease (AD) and recent findings suggest that network abnormalities and interneurons dysfunction contribute to cognitive deficits. Somatostatin (SOM) and Neuropeptide Y (NPY) are two neuropeptides which are expressed in GABAergic interneurons with different fates in AD the former only being markedly affected. The aim of this study was to analyze CSF SOM, NPY and CSF Aβ<sub>1–42</sub>; T-Tau, P-Tau relationships in 43 elderly mild cognitively impairment (MCI) participants from the Biomarker of AmyLoïd pepTide and AlZheimer’s disease Risk (BALTAZAR) cohort. In these samples, CSF SOM and CSF Aβ<sub>1–42</sub> on the one hand, and CSF NPY and CSF T-Tau and P-Tau on the other hand are positively correlated. CSF SOM and NPY concentrations should be further investigated to determine if they can stand for early AD biomarkers.</p><p>Clinical Trial Registration: <ext-link ext-link-type="uri" xlink:href="http://www.ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">www.ClinicalTrials.gov</ext-link>, identifier #NCT01315639.</p>